## DXCM: DexCom, Inc. - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_10 at 3.2% in lower entry zone (3.0-6.0%), top quartile (78th pct) cross-sectional ranking. Short-term MRS_5 (1.9%) confirms momentum alignment. Strong momentum (+1.1% 5-day acceleration). Outperforming sector by 6.7%.

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($63.14)
- **If Wrong:** Exit if MRS_10 drops below entry zone or breaks stop
- **Invalidation:** MRS_10 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 1, Bearish: 0)

**1. DXCM DEADLINE: DexCom, Inc. Investors Encouraged to Contact Kirby McInerney LLP Before Looming Deadline in Lawsuit**
- Source: FOX40 News | 20251210T010925 | Neutral | Relevance: 100%
-  Investors in DexCom, Inc. (NASDAQ:DXCM) are urged to contact Kirby McInerney LLP regarding a securities fraud class action lawsuit, with a lead plaintiff deadline of December 26, 2025. The lawsuit alleges that DexCom made unauthorized design changes to its G6 and G7 glucose monitors, leading to inaccurate readings, health risks, and a decline in stock prices due to regulatory scrutiny and downgrades. The firm is seeking to represent investors who suffered losses during the period of January 8, 2024, through September 17, 2025.

**2. Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of December 26, 2025 in DexCom, Inc. Lawsuit â€“ DXCM**
- Source: GlobeNewswire | 20251209T220805 | Neutral | Relevance: 99%
-  Levi & Korsinsky, LLP is reminding investors of DexCom, Inc. (DXCM) about a class action securities lawsuit. The lawsuit alleges that DexCom made material design changes to its glucose monitoring products (G6 and G7) without FDA authorization, rendering them less reliable and potentially harmful. Investors who suffered losses between January 8, 2024, and September 17, 2025, have until December 26, 2025, to request to be appointed as lead plaintiff.

**3. DexCom, Inc. (DXCM) Investors: December 26, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser**
- Source: WREG.com | 20251208T131355 | Neutral | Relevance: 99%
- Lieff Cabraser Heimann & Bernstein, LLP urges DexCom, Inc. (DXCM) investors who purchased securities between January 8, 2024, and September 17, 2025, to join a securities class action. The lawsuit alleges DexCom made misleading statements regarding design changes to its G6 and G7 CGM devices without FDA approval, leading to compromised accuracy and significant stock declines following negative disclosures and an FDA Warning Letter. Investors must apply to be lead plaintiff by December 26, 2025.

**4. DexCom, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before December 26, 2025 to Discuss Your Rights - DXCM**
- Source: PR Newswire | 20251209T000759 | Neutral | Relevance: 99%
-  The Gross Law Firm has issued a notice to shareholders of DexCom, Inc. (NASDAQ: DXCM) regarding a class action lawsuit. The lawsuit alleges that DexCom made unauthorized material design changes to its glucose monitoring products, the G6 and G7, rendering them less reliable and presenting health risks. Shareholders who purchased DXCM shares between January 8, 2024, and September 17, 2025, are encouraged to contact the firm before the December 26, 2025, deadline to discuss their rights and potential lead plaintiff appointment.

**5. DexCom, Inc. (DXCM) Investors: December 26, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser**
- Source: WTRF | 20251208T130827 | Neutral | Relevance: 99%
-  Lieff Cabraser Heimann & Bernstein, LLP is encouraging investors in DexCom, Inc. (NASDAQ:DXCM) to contact them regarding a securities class action lawsuit. The lawsuit alleges that DexCom made false and misleading statements about its G6 and G7 continuous glucose monitoring systems, specifically regarding design changes without FDA approval, accuracy issues, and app connectivity problems, which led to significant stock price declines. The deadline to apply to be a lead plaintiff in this class action is December 26, 2025.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $75 | $63 | +19% |
| 2025-11-25 | Evercore ISI Gr | $68 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | up | Overweight |
| 2025-11-25 | Evercore ISI Gr | init | In-Line |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.14M) |
| Sells | 3 ($0.45M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 61.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Tudor Investment Cor: 17.7% (+100.0%)
- Vanguard Group Inc: 12.7% (+2.4%)
- Blackrock Inc.: 10.0% (-0.5%)
- State Street Corpora: 4.3% (-0.0%)
- BAILLIE GIFFORD & CO: 4.1% (-4.9%)

### Key Risks

1. Long-term trend broken: trading 9.6% below SMA200.
2. Market regime shift could impact high-beta names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_10 improving +1.1% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 0.86 indicates undervaluation relative to growth. Quality metrics strong (ROE 31%, margin 16%). Analyst sentiment positive (1 raises, avg +19%). Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $26.5B |
| Beta | 1.51 |
| 52W Range | $54.11 - $93.25 |
| Short Interest | 4.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.86 |
| Forward P/E | 27.2 |
| Current P/E | 32.7 |
| YoY Growth | 20.4% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from 2.1% to 3.2% (+1.1% in 5 days), confirming momentum buildup. Currently in lower STRENGTH zone (3.0-6.0%), cross-sectional ranking at 78th percentile. MRS_5 at 1.9% confirms short-term momentum alignment. Outperforming sector by 6.7pp, stock-specific strength. Below SMA200 (0.90x), long-term trend not supportive. MACD histogram positive (0.87), confirming momentum.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 3.23% (CS: 79) | Strong |
| RSI_14 | 65.2 | Neutral |
| MACD Histogram | 0.87 | Bullish |
| vs SMA20 | 1.083x | Above |
| vs SMA50 | 1.055x | Above |
| vs SMA200 | 0.904x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $67.56
- **Stop Loss:** $63.14 (6.5% risk)
- **Target:** $74.19 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 113
- **Position Value:** $7,634.28
- **Portfolio %:** 7.63%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with signs of improving risk appetite. Multiple major banks lowering prime rates suggest a dovish tilt in financial conditions ahead of the FOMC, while volatility remains subdued and breadth is moderate. Key drivers are easing lending rates, stable macro data, and improving sentiment, but selectivity is needed due to sector divergences.*

### Earnings

**Next:** 2026-02-12 (Est: $0.65)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.57 | $0.61 | +7.5% |
| 2025Q2 | $0.44 | $0.48 | +8.2% |
| 2025Q1 | $0.33 | $0.32 | -2.6% |
| 2024Q4 | $0.50 | $0.45 | -9.9% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*